CURAXIS PHARMACEUTICAL Corp

Operating margin

—

Net margin

—

Return on equity

1070.9%

Return on assets

−13443.8%

Return on capital (ROCE)

—

Liabilities / assets

1355.3%

Debt / equity

—

Book value / share

$-103.10

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

−1569.8%clean

Piotroski F-Score

2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer changeJul 30, 2012
• Other material eventJan 18, 2012
• Director / officer change · Amended charter or bylawsJun 30, 2011
• Other material eventNov 19, 2010
• Regulation FD disclosureOct 26, 2010
• Entered a material agreement · Unregistered equity sale · Amended charter or bylawsOct 1, 2010
• Amended charter or bylawsSep 29, 2010
• Entered a material agreement · Unregistered equity saleSep 21, 2010

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.